| Trial registration number
|
NCT04530409 |
Full text link
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov
|
https://clinicaltrials.gov/show/NCT04530409
|
First author
Last imported at : Jan. 20, 2022, 11:30 a.m.
Source : ClinicalTrials.gov
|
Emad R Issak, MD
|
Contact
Last imported at : Jan. 20, 2022, 11:30 a.m.
Source : ClinicalTrials.gov
|
dr.emad.r.h.issak@gmail.com
|
Registration date
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov
|
2020-08-28
|
Recruitment status
Last imported at : Nov. 3, 2022, 4 a.m.
Source : ClinicalTrials.gov
|
Not recruiting
|
Study design
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov
|
RCT
|
Allocation
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov
|
Randomized
|
Design
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov
|
Parallel
|
Masking
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov
|
Open label
|
Center
Last imported at : March 15, 2023, 4 a.m.
Source : ClinicalTrials.gov
|
single-center
|
Study aim
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov
|
Treatment
|
Inclusion criteria
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov
|
inclusion criteria:
- any case with covid-19 more than or equal to 18 years
- mild and moderate severity
|
Exclusion criteria
Last imported at : Jan. 20, 2022, 11:30 a.m.
Source : ClinicalTrials.gov
|
severe to critical covid-19
any contra-indication for the interventional drug
mentally disabled cases
|
Number of arms
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov
|
2
|
Funding
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov
|
ClinAmygate
|
Inclusion age min
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov
|
18
|
Inclusion age max
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov
|
100
|
Countries
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov
|
Egypt
|
Type of patients
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov
|
Mild/moderate disease at enrollment
|
Severity scale
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov
|
2: Mild/moderate disease at enrollment
|
Total sample size
Last imported at : Jan. 20, 2022, 11:30 a.m.
Source : ClinicalTrials.gov
|
752
|
primary outcome
Last imported at : Jan. 20, 2022, 11:30 a.m.
Source : ClinicalTrials.gov
|
28-days mortality;Percentage of cases that will need hospitalization;Percentage of cases that will need oxygen supplementation
|
Notes
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov
|
None
|
Phase
Last imported at : Feb. 25, 2021, 7:58 p.m.
Source : ClinicalTrials.gov
|
Phase 4
|
Arms
Last imported at : Jan. 20, 2022, 11:30 a.m.
Source : ClinicalTrials.gov
|
[{"arm_notes": "Early-Dexamethasone:\nearly use of dexamethasone as early as laboratory evidence of high inflammatory markers\nOther Name: Dexamethasone", "treatment_id": 400, "treatment_name": "Dexamethasone", "treatment_type": "Corticosteroids", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "Late-Dexamethasone:\nUse of dexamethasone on deterioration of the cases with increased severity\nOther Name: Dexamethasone", "treatment_id": 400, "treatment_name": "Dexamethasone", "treatment_type": "Corticosteroids", "pharmacological_treatment": "Pharmacological treatment"}]
|